Evidence map›Paper›PMID 30201396›Full record

ArticleAntiviral research2018

CpAMs induce assembly of HBV capsids with altered electrophoresis mobility: Implications for mechanism of inhibiting pgRNA packaging.

Shuo Wu, Yue Luo, Usha Viswanathan, John Kulp, Junjun Cheng, Zhanying Hu, Qifang Xu, Yan Zhou, Guo-Zhong Gong, Jinhong Chang and 2 more

Abstract read
In one paragraph

Article in Antiviral research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Synthesis of 4-oxotetrahydropyrimidine-1(2H)-carboxamides derivatives as capsid assembly modulators of hepatitis B virus.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2021
    Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shuo WuInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China; Baruch S. Blumberg Institute, Doylestown, PA, USA.
Yue LuoBaruch S. Blumberg Institute, Doylestown, PA, USA; Institute of Hepatology, Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Usha ViswanathanBaruch S. Blumberg Institute, Doylestown, PA, USA.
John KulpBaruch S. Blumberg Institute, Doylestown, PA, USA.
Junjun ChengBaruch S. Blumberg Institute, Doylestown, PA, USA.
Zhanying HuBaruch S. Blumberg Institute, Doylestown, PA, USA.
Qifang XuFox Chase Cancer Center, Philadelphia, PA, USA.
Yan ZhouFox Chase Cancer Center, Philadelphia, PA, USA.
Guo-Zhong GongInstitute of Hepatology, Second Xiangya Hospital, Central South University, Changsha, Hunan Province, China.
Jinhong ChangBaruch S. Blumberg Institute, Doylestown, PA, USA.
Yuhuan LiInstitute of Medicinal Biotechnology, Chinese Academy of Medical Science, Beijing, China. Electronic address: yuhuanlibj@126.com.
Ju-Tao GuoBaruch S. Blumberg Institute, Doylestown, PA, USA. Electronic address: ju-tao.guo@bblumberg.org.

Funding

Evaulation of therapeutic benefits of HBV nucleocapsid assembly inhibitorsR01AI113267 · NIAID · DREXEL UNIVERSITY · PI DU, YANMING, GUO, JU-TAO · 2014 to 2018
$2.9M
NIAID NIH HHS R01 AI113267
6 · The paper itself

Abstract

Native agarose gel electrophoresis-based particle gel assay has been commonly used for examination of hepatitis B virus (HBV) capsid assembly and pregenomic RNA encapsidation in HBV replicating cells. Interestingly, treatment of cells with several chemotypes of HBV core protein allosteric modulators (CpAMs) induced the assembly of both empty and DNA-containing capsids with faster electrophoresis mobility. In an effort to determine the physical basis of CpAM-induced capsid mobility shift, we found that the surface charge, but not the size, of capsids is the primary determinant of electrophoresis mobility. Specifically, through alanine scanning mutagenesis analysis of twenty-seven charged amino acids in core protein assembly domain and hinge region, we showed that except for K7 and E8, substitution of glutamine acid (E) or aspartic acid (D) on the surface of capsids reduced their mobility, but substitution of lysine (K) or arginine (R) on the surface of capsids increased their mobility in variable degrees. However, alanine substitution of the charged amino acids that are not exposed on the surface of capsid did not apparently alter capsid mobility. Hence, CpAM-induced electrophoresis mobility shift of capsids may reflect the global alteration of capsid structure that changes the exposure and/or ionization of charged amino acid side chains of core protein. Our findings imply that CpAM inhibition of pgRNA encapsidation is possibly due to the assembly of structurally altered nucleocapsids. Practically, capsid electrophoresis mobility shift is a diagnostic marker of compounds that target core protein assembly and predicts sensitivity of HBV strains to specific CpAMs.

Indexed as

Virus AssemblyAllosteric RegulationAntiviral AgentsCapsidCapsid ProteinsElectrophoresisElectrophoretic Mobility Shift AssayHepatitis B Core AntigensHepatitis B virusHep G2 CellsHumansRNARNA, ViralViral Core ProteinsVirus ReplicationAntiviral AgentsCapsid ProteinsHepatitis B Core AntigenspgRNARNARNA, ViralViral Core Proteins

Identifiers

PMID30201396
PMCPMC8034245

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.